Test Price
2,800 AED✅ Home Collection Available
CFB Gene Sequencing for Atypical Hemolytic Uremic Syndrome (aHUS) – Molecular Diagnostics in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 Accredited NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Tet Clinical Guidance for result interpretation by a Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) test screens the entire CFB gene (Complement Factor B) for pathogenic variants. CFB dysregulation is a primary driver of atypical Hemolytic Uremic Syndrome (aHUS), a rare but serious condition causing thrombotic microangiopathy. This definitive molecular diagnosis guides targeted anti-complement therapy and enables accurate familial risk assessment.
| Feature | Our NGS Comprehensive Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | NGS (Whole Gene + Regulatory Regions) | Sanger (Targeted Exons Only) |
| Variant Detection | 99.9% Diagnostic Sensitivity, includes deep intronic variants | ~95% sensitivity, misses non-exonic variants |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Cost in UAE (AED) | 2,800 | 3,200 – 4,500 |
Physician Insight & Safety Protocols
"Genetic testing for aHUS provides a definitive molecular roadmap, guiding complement-based therapies and familial cascade screening. It is a powerful tool, but must be interpreted alongside clinical and biochemical findings for optimal patient outcomes."
— Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Safety & Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. Genetic test outcomes should guide, not abruptly alter, ongoing therapy, especially immunosuppressants or complement inhibitors.
Safety Exclusion Criteria & Emergency Indicators
- Exclusion: Patients unable to give informed consent; minors without legal guardian authorization as per UAE Federal Law.
- Exclusion: Recent allogeneic blood transfusion (within 4 weeks) may interfere with germline DNA analysis.
- Emergency Red Flag: Sudden oliguria, severe pallor, petechiae, or altered mental status – signs of acute thrombotic microangiopathy require immediate ER care.
- Emergency Red Flag: Active hemolytic crisis with rapid hemoglobin drop – do not wait for genetic results; seek emergency nephrology consultation.
Patient FAQ & Clinical Guidance
1. What is a CFB gene mutation and how does it cause aHUS?
The CFB gene provides instructions for making Complement Factor B, a protein essential to the complement immune system. Pathogenic mutations cause overactivation of this system, leading to attack on blood vessels and organs, manifesting as atypical Hemolytic Uremic Syndrome (aHUS).
2. How is the CFB genetic test performed?
The test requires a standard peripheral whole blood sample (3-5 ml in an EDTA tube). Our accredited laboratory extracts DNA and performs Next-Generation Sequencing (NGS) specifically targeting the CFB gene, including exon and intron regions.
3. Who should consider getting the CFB gene test?
This test is indicated for patients with unexplained thrombotic microangiopathy (TMA), suspected atypical HUS, or a family history of aHUS. It helps distinguish aHUS from other TMAs like STEC-HUS or TTP, enabling precise targeted therapy.
4. What is the turnaround time for the CFB genetic test results?
The processing and validation of the NGS data requires a standard turnaround time of 3 to 4 weeks. This ensures comprehensive bioinformatic analysis and clinical interpretation by our team of genetic specialists.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the strictest regulatory compliance in the UAE, holding a valid DHA Facility License (No. 1143). Our data security and clinical protocols align with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Federal Decree-Law No. 4 of 2016 on Medical Liability for clinical safety and patient consent.
Clinical & Logistical Metadata
| Test Name | CFB Gene Sequencing (aHUS Panel) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Extracted DNA |
| Methodology Used | Next-Generation Sequencing (NGS) – Whole Gene & Regulatory Regions |
| ICD-10-CM Code | D59.3 (Hemolytic-uremic syndrome) |
| LOINC Code | 101078-3 (CFB gene mutation analysis) |
| DHA Facility License & Address | DNA Labs UAE | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians